Перспективы и преимущества применения эксенатида в управлении сахарным диабетом типа 2
Перспективы и преимущества применения эксенатида в управлении сахарным диабетом типа 2
Перспективы и преимущества применения эксенатида в управлении сахарным диабетом типа 2. Consilium Medicum. 2009; 11 (12): 39–43.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Список литературы
1. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331–9.
2. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32: 805–22.
3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583–9.
4. Yki-Jдrvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Molec Med 2005; 5: 287–95.
5. Williamson DF, Thompson TJ, Thun M et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499–504.
6. Raz I, Eldor R, Cernea S et al. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005; 21: 3–14.
7. Webb DM, Wintle M, Malone JK. Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes. Drug Devel Res 2006; 67: 666–76.
8. Zinman B, Hoogwerf BJ, Garcia SD et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007; 146: 477–85.
9. Mack CM, Laugero KD, Liu Q et al. Therapeutic applications of incretin mimetics for metabolic diseases: preclinical studies. Drug Dev Res 2006; 67: 553–8.
10. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628–35.
11. DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–100.
12. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083–91.
13. Buse JB, Klonoff DC, Nielsen LL et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139–53.
14. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on HbA1с, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436–47.
15. Declaration of Helsinski: Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 1997; 277: 925–6.
16. Ding X, Saxena NK, Lin S et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173–81.
17. Tushuizen ME, Bunck MC, Pouwels PJ et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006; 26: 1015–7.
2. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32: 805–22.
3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583–9.
4. Yki-Jдrvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Molec Med 2005; 5: 287–95.
5. Williamson DF, Thompson TJ, Thun M et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499–504.
6. Raz I, Eldor R, Cernea S et al. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005; 21: 3–14.
7. Webb DM, Wintle M, Malone JK. Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes. Drug Devel Res 2006; 67: 666–76.
8. Zinman B, Hoogwerf BJ, Garcia SD et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007; 146: 477–85.
9. Mack CM, Laugero KD, Liu Q et al. Therapeutic applications of incretin mimetics for metabolic diseases: preclinical studies. Drug Dev Res 2006; 67: 553–8.
10. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628–35.
11. DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–100.
12. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083–91.
13. Buse JB, Klonoff DC, Nielsen LL et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139–53.
14. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on HbA1с, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436–47.
15. Declaration of Helsinski: Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 1997; 277: 925–6.
16. Ding X, Saxena NK, Lin S et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173–81.
17. Tushuizen ME, Bunck MC, Pouwels PJ et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006; 26: 1015–7.
Авторы
Т.Ю.Демидова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.